Prestige Q3 revenue $283.4M, down 2.4% YoY; adjusted EPS $1.14 vs $1.22

Prestige Consumer Healthcare Inc.

2026-Q3 EPS reported $2.78 revenue$807,088,000

GAAP diluted EPS $0.97; adjusted diluted EPS $1.14 (down from $1.22); net income $46.7M.
Narrowed FY2026 revenue outlook to ~$1.1B from $1.1-1.115B; adjusted EPS ~$4.54.
Repurchased ~0.8M shares in Q3 for $45.8M; YTD repurchases ~2.3M shares at $155.6M.
Closed acquisition of eye care supplier Pillar5 Pharma in December 2025.
Clear Eyes supply constraints continue; management expects supply improvements in coming quarters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.